

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6488464

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CORAMED TECHNOLOGIES, LLC	01/10/2020
RECEIVING PARTY DATA	
Name:	HAEMONETICS CORPORATION
Street Address:	400 WOOD ROAD
City:	BRAINTREE
State/Country:	MASSACHUSETTS
Postal Code:	49740
PROPERTY NUMBERS Total: 10	
Property Type	Number
Patent Number:	8236568
Application Number:	11756801
Application Number:	15423701
Patent Number:	7879615
Patent Number:	9068966
Patent Number:	9575078
Patent Number:	9599601
Patent Number:	10357769
Application Number:	16434194
Application Number:	15526757
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2318387482
Email:	asitko@anthonysitko.com
Correspondent Name:	ANTHONY G SITKO PLC
Address Line 1:	PO BOX 315
Address Line 4:	HARBOR SPRINGS, MICHIGAN 49740
NAME OF SUBMITTER:	ANTHONY G SITKO

SIGNATURE:	/Anthony G Sitko, 36278/
DATE SIGNED:	01/11/2021
Total Attachments: 5 source=Patent Assignment CoraMed Technologies#page1.tif source=Patent Assignment CoraMed Technologies#page2.tif source=Patent Assignment CoraMed Technologies#page3.tif source=Patent Assignment CoraMed Technologies#page4.tif source=Patent Assignment CoraMed Technologies#page5.tif	

PATENT ASSIGNMENT

This Patent Assignment (this "Assignment") is made effective this 13th day of January, 2020, by and between CoraMed Technologies, LLC, a Delaware limited liability company (the "Company"), and Haemonetics Corporation, a Massachusetts corporation ("Buyer").

WHEREAS, Company possesses certain rights in and to, the patents and patent applications (and patents issuing on such applications) listed in Schedule A attached hereto and incorporated by reference, and the invention(s) described and/or claimed in such patents and patent applications (collectively, the "Patent Rights"); and

WHEREAS, Buyer and Company have entered into that certain Asset Purchase Agreement dated January 13, 2020 (the "Purchase Agreement"), pursuant to which Buyer is acquiring all of Company's right, title and interest in and to substantially all of the assets of the Business (as defined in the Purchase Agreement), including the Patent Rights.

NOW, THEREFORE, to all whom it may concern be it known that for and in consideration of good and valuable consideration including consideration agreed upon between Company and Buyer under the Purchase Agreement, the receipt and sufficiency of which is hereby acknowledged, Company has sold, assigned and transferred and by these presents does hereby sell, assign and transfer unto Buyer, its successors, assigns, and legal representatives, Company's entire right, title and interest in and throughout the United States of America, its territories and all foreign countries, in and to the invention(s) described and/or claimed in the Patent Rights (the "Inventions"), together with Company's entire right, title and interest in and to the Patent Rights and such other patents as may issue thereon or claim priority under United States law or international convention, including but not limited to non-provisionals, continuations, divisionals, reissues, reexaminations, extensions, and substitutions of patents and patent applications within the Patent Rights or such other patents, and any right, title and interest Company may have in applications to which the Patent Rights claim priority; the Inventions and the Patent Rights to be held and enjoyed by Buyer for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by Company had this assignment and sale not been made; and Company hereby conveys all of its rights arising under or pursuant to any and all United States laws and international agreements, treaties or laws relating to the protection of industrial property by filing any such applications for patent, including but not limited to any cause(s) of action and damages accruing prior to this assignment. Company hereby acknowledges that this assignment, being of Company's entire right, title and interest in and to the Inventions and the Patent Rights carries with it the right in Buyer to apply for and obtain from competent authorities in all countries of the world any and all patents by attorneys and agents of Buyer's selection and the right to procure the grant of all patents to Buyer in its own name as Buyer of Company's entire right, title and interest therein;

AND, Company hereby further agrees for itself and its successors, assigns, agents, and legal representatives to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the Patent Rights to Buyer, its successors, assigns, and legal representatives, as well as to third parties at the

request of Buyer including the execution of documents (including, without limitation, petitions, specifications, oaths, assignments, disclaimers, declarations and affidavits) relating to non-provisional, substitution, continuation, divisional, reissue, reexamination, or corresponding foreign or international patent applications within the Patent Rights, as requested by Buyer, and generally do everything possible to aid Buyer, its successors, assigns and legal representatives to obtain, record, maintain, and enforce full protection for the Inventions in all countries, but in each instance at Buyer's reasonable expense;

AND, Company hereby further agrees to provide statements or testimony in any interference or other proceeding in which any of the Patent Rights may be involved;

AND, Company hereby warrants that it has not knowingly conveyed to others any rights in the Patent Rights or the Inventions or any license to use the same or to make, use or sell anything embodying or utilizing any of the Inventions, and that it has good right to assign the Inventions and the Patent Rights without encumbrance;

AND, Company does hereby authorize the Director of the United States Patent & Trademark Office, and the empowered officials of all other governments whose duty it is to record patents, applications and title thereto, to record the Patent Rights and title thereto as the property of Buyer, its successors, assigns, or legal representatives in accordance with the terms of this instrument;

AND, Company does hereby authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue such Patent Rights or patents as shall be granted upon the Patent Rights, or applications based thereon, to Buyer, its successors, assigns, or legal representatives;

AND, Company hereby warrants that it is the sole owner of the Patent Rights.

Buyer and Company also agree that multiple copies of this Assignment of Patent Rights may be executed, each of which shall be deemed an original, and each of which shall be valid and binding upon Buyer and Company.

No modifications of or additions to this Assignment shall have effect unless in writing and properly executed by both Company and Buyer, making specific reference to this Assignment by date, parties, and subject matter. This Assignment and the rights and obligations of the parties hereunder shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts, without regard to its conflict of laws principles.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, each of the parties hereto has executed this Assignment, or has caused this Agreement to be executed by its respective officer thereunto duly authorized, all as of the day and year first above written.

CoraMed Technologies, LLC:

Name:

Signature:

Title:

GABRIEL DAVIV

[Signature]

PRESIDENT

On this 10th day of January, 2020, before me, the undersigned Notary Public, personally appeared Gabriel Daviv, proved to me through satisfactory evidence of identification, which was/were IL Driver License, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignor and executed this document of his/her own free will.

Lina Khayel
Signature of Notary

My Commission Expires: 11/27/2021

(Seal)



Haemonetics Corporation:

Name:

Signature:

Title:

Christopher Simon

[Signature]



President, CEO

On this 31 day of JANUARY, 2020, before me, the undersigned Notary Public, personally appeared Christopher Simon, proved to me through satisfactory evidence of identification, which was/were Driver License, to be the person whose name is signed on the preceding or attached document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief. The above-indicated individual is duly authorized to execute this document singly on behalf of Assignee and executed this document of his/her own free will.

[Signature]
Signature of Notary

My Commission Expires: _____

(Seal)



SCHEDULE A

Title	Patent / Serial No.	Country
Hemostasis Analyzer and Method	7,261,861	US
	20044235103	AU
	10570364 C	CN
	EP1618375	EP (including Validation in DE, DK, ES, FR and UK)
	299738	IN
	200804065	IN
	4352145	JP
	1784599	CN
	2006524824	JP
	2009180743	JP
Method of Analyzing Hemostasis	8,236,568	US
	101713775	CN
	EP2690437	EP (including Validation in DE, ES, FR, IT and UK)
	5079740	JP
Resonant Frequency Hemostasis Analyzer	11/756,801	US
	15/423,701	US
Hemostasis Analyzer and Method	7,879,615	US
	EP1977236	EP (including Validation in AT, BE, CH, DE, DK, FR, IE, IT, SE and UK)
Apparatus and Cartridge for Hemostasis Testing	9068966	US
	2014227711	AU
	2904616	CA
	201480007938.4	CN
	14 722 459.6	EP

Schedule A to Patent Assignment

ACTIVE/101689906.4

PATENT
REEL: 054870 FRAME: 0786

Title	Patent / Serial No.	Country
	5518/CHENP/2015	IN
	10-2015-7029458	KR
	2015144208	RU
	515361141	SA
	2015/01716	ZA
Method for Hemostasis Testing	9,575,078	US
Apparatus and Cartridge for Hemostasis Testing	9,599,601	US
Apparatus and Cartridge for Hemostasis Testing	10,357,769	US
Method for Hemostasis Testing	16/434,194	US
Apparatus and Method to Determine Stroke Subtype	15/526,757	US
	201580073453.X	CN
	15 805 345.5 (EP3218723)	EP
	2017-544844	JP
	2017534069	JP

ACTIVE/101689906.4

Schedule A to Patent Assignment

RECORDED: 01/11/2021

PATENT
REEL: 054870 FRAME: 0787